Endocyte Pursuing Phase 3 Trial of 177Lu-PSMA-617 in Metastatic PC

Endocyte Pursuing Phase 3 Trial of 177Lu-PSMA-617 in Metastatic PC
Endocyte announced it will move PSMA-617 quickly into Phase 3 development in prostate cancer after it licensed the compound from German ABX. The trial, for which the company has yet to seek approval, likely will launch by early 2018. Although the compound, which is coupled to a radioactive molecule called 177Lu to fight cancer, has

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.


  1. Stephen B. Strum, MD, FACP says:

    The use of 68Ga-PSMA PET/CT for imaging and 177Lu-PSMA-617 for treatment is a two armed approach called theranostics. The Germans have led the way on this as well as on most imaging advances in prostate cancer for some time now. I do not know why there is so much of a lag (averaging at least ten years) between what the Germans come out with and our eventually translating this to our patients. I call this process read, digest, assimilate and translate (RDAT) and we here in the USA are failing miserably to do this. I saw this with NaF PET/CT and continue to see patients getting the highly insensitive Tc99 to rule out bone metastases when NaF PET/CT is superior and proven to be so in head-to-head studies in the literature that date back ten years. I see major advances also coming out of China, S. Korea and Japan and wonder what in the world is wrong with imaging studies in the USA.

Leave a Comment

Your email address will not be published. Required fields are marked *